Cbi-1214
Metastatic Colon Cancer
Cartography BiosciencesPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
33 Active assets in the Metastatic Colon Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Fudan University | Phase 4 | BBB |
Fruquintinib Peking University | Phase 3 | BBB |
DEXAMETHASONE Fudan University | Phase 3 | BB |
Capecitabine Jun Huang | Phase 3 | BB |
Irinotecan Jun Huang | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Cbi-1214 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →